Discovery of novel GPVI receptor antagonists by structure-based repurposing.

Taylor, L., Vasudevan, S. R., Jones, C. I. ORCID: https://orcid.org/0000-0001-7537-1509, Gibbins, J. M. ORCID: https://orcid.org/0000-0002-0372-5352, Churchill, G. C., Campbell, R. D. and Coxon, C. H. (2014) Discovery of novel GPVI receptor antagonists by structure-based repurposing. PLoS ONE, 9 (6). e101209. ISSN 1932-6203 doi: 10.1371/journal.pone.0101209

Abstract/Summary

Inappropriate platelet aggregation creates a cardiovascular risk that is largely managed with thienopyridines and aspirin. Although effective, these drugs carry risks of increased bleeding and drug 'resistance', underpinning a drive for new antiplatelet agents. To discover such drugs, one strategy is to identify a suitable druggable target and then find small molecules that modulate it. A good and unexploited target is the platelet collagen receptor, GPVI, which promotes thrombus formation. To identify inhibitors of GPVI that are safe and bioavailable, we docked a FDA-approved drug library into the GPVI collagen-binding site in silico. We now report that losartan and cinanserin inhibit GPVI-mediated platelet activation in a selective, competitive and dose-dependent manner. This mechanism of action likely underpins the cardioprotective effects of losartan that could not be ascribed to its antihypertensive effects. We have, therefore, identified small molecule inhibitors of GPVI-mediated platelet activation, and also demonstrated the utility of structure-based repurposing.

Item Type	Article
URI	https://reading-clone.eprints-hosting.org/id/eprint/40525
Identification Number/DOI	10.1371/journal.pone.0101209
Refereed	Yes
Divisions	Interdisciplinary centres and themes > Institute for Cardiovascular and Metabolic Research (ICMR) Life Sciences > School of Biological Sciences > Biomedical Sciences
Uncontrolled Keywords	platelets, thrombosis, haemostasis, GPVI
Publisher	Public Library of Science
Download/View statistics	View download statistics for this item